280 Utah Avenue
South San Francisco
Annexon Biosciences is leading the development of therapeutic products that halt the progression of CMND. Our antibody pipeline is based on breakthrough research involving the classical complement pathway and the unique role of its initiating molecule, C1q, in triggering the loss of nerve connections and inducing inflammation in neurologic and ophthalmic disorders.
CEO: Douglas Love, Esq
Chief Scientific Officer: Ted Yednock, PhD
Chief Medical Officer: Mario Saltarelli, MD, PhD